<DOC>
	<DOCNO>NCT00632255</DOCNO>
	<brief_summary>Imatinib revolutionise treatment chronic myeloid leukaemia ( CML ) . The first clinical trial conduct 1998 patient advanced disease , 2002 imatinib establish standard therapy patient include recently diagnose . In spite overwhelming evidence efficacy still need gain knowledge issue relate long term treatment imatinib patient respond good others , development side effect quality life .</brief_summary>
	<brief_title>Long Term Therapy With Imatinib : Development Late Side Effects Compliance Treatment</brief_title>
	<detailed_description>We plan follow prospectively cohort CML patient order study compliance therapy , pharmacological level imatinib prevalence side effect . We expect able correlate actual dose receive , pharmacological level drug blood , change level residual disease ( measure Q−PCR ) various time point . We also want gain insight relationship compliance therapy specific side effect compliance duration treatment . We also assess adherence imatinib therapy increase drug dose part standard treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients CML treat imatinib ( Glivec® ) within 6 month diagnosis first line therapy . Initial therapy hydroxyurea permit . Unable give consent . Unable communicate medical nursing staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Long term Imatinib therapy compliance</keyword>
	<keyword>Newly diagnose</keyword>
	<keyword>Late side effect</keyword>
</DOC>